JP2000136124A - Skin lotion - Google Patents

Skin lotion

Info

Publication number
JP2000136124A
JP2000136124A JP10309809A JP30980998A JP2000136124A JP 2000136124 A JP2000136124 A JP 2000136124A JP 10309809 A JP10309809 A JP 10309809A JP 30980998 A JP30980998 A JP 30980998A JP 2000136124 A JP2000136124 A JP 2000136124A
Authority
JP
Japan
Prior art keywords
skin
scientific name
external preparation
oligopeptide
chlorella
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP10309809A
Other languages
Japanese (ja)
Inventor
Kazutoshi Sakamoto
和俊 阪本
Mikio Miyahara
幹夫 宮原
Takeshi Shigematsu
剛 重松
Masako Tsutsumi
雅子 堤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pias Corp
Original Assignee
Pias Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pias Corp filed Critical Pias Corp
Priority to JP10309809A priority Critical patent/JP2000136124A/en
Publication of JP2000136124A publication Critical patent/JP2000136124A/en
Pending legal-status Critical Current

Links

Abstract

PROBLEM TO BE SOLVED: To obtain a skin lotion capable of keeping the skin elastic, fresh and young by controlling a skin differentiation and a skin proliferation by inhibiting an elastase activity. SOLUTION: This skin lotion comprises either or both of (1) a component comprising an oligopeptide having an amino acid sequence consisting of Val-Gly- Val-Ala-Pro-Gly, a polypeptide, a protein or an extract containing the oligopeptide and (2) a component comprising one or more kinds of extracts selected from the extract of Chlorella (Chlorella), Ascophyllum (scientific name: Ascophyllum Nodosum), Silybum marianum Gaertn (scientific name: Silybum marianum (L) Gaertn) or Centella asiatica (scientific name: Centella asiatica (L) Urb).

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、皮膚外用剤に関
し、特に、弾力性のあるみずみずしい皮膚をつくる皮膚
外用剤に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an external preparation for skin, and more particularly to an external preparation for skin which produces elastic and fresh skin.

【0002】[0002]

【従来の技術】近年、皮膚の老化に関する研究が急速に
進み、組織レベル、細胞レベル又は分子レベルでの皮膚
の老化の過程が明かになったきた。即ち、皮膚の老化は
遺伝子レベルでの避けることのできない現象である一
方、紫外線等の太陽光の影響や乾燥、酸化などの環境要
因によっても促進されることがわかってきた。
2. Description of the Related Art In recent years, studies on skin aging have progressed rapidly, and the process of skin aging at a tissue level, a cellular level or a molecular level has been revealed. That is, it has been found that skin aging is a phenomenon that cannot be avoided at the genetic level, but is also promoted by the influence of sunlight such as ultraviolet rays and environmental factors such as drying and oxidation.

【0003】具体的には、酵素やラジカルの作用によっ
て組織が分解、変性されることにより皮膚が弾力性を失
い、老化が促進される。
[0003] Specifically, the tissue is decomposed and denatured by the action of enzymes and radicals, whereby the skin loses elasticity and aging is accelerated.

【0004】例えば、ケラチノサイトの正常な増殖や分
化を維持することにより、適度な水分を角層内に保留で
き、小皺、落屑、乾燥を防いでみずみずしい皮膚を保つ
ことができることが知られている。
For example, it is known that by maintaining normal proliferation and differentiation of keratinocytes, appropriate moisture can be retained in the stratum corneum, and fine wrinkles, desquamation, and drying can be prevented and fresh skin can be maintained.

【0005】また、真皮に存在するエラスチンは、酵素
エラスターゼやラジカルによって分解、変性され、この
エラスチンが分解、変成されることにより皮膚が弾力性
を失い、老化が促進されることが知られている。
It is known that elastin present in the dermis is decomposed and denatured by the enzyme elastase and radicals, and the elastin is decomposed and denatured, whereby the skin loses elasticity and aging is promoted. .

【0006】更に、本発明者らは、皮膚の老化現象につ
いて鋭意研究を重ねた結果、前記エラスチンは、真皮の
みならず表皮にも存在し、この表皮のエラスチンがエラ
スターゼやラジカル等によって分解され、これが表皮細
胞の正常な角化に影響を与え、ハリ、小皺、クスミ、乾
燥等、皮膚の老化の原因となること、即ち、エラスター
ゼの活性を阻害することが、真皮のエラスチンの老化を
抑制するのみならず、表皮のエラスチンをも正常に保
ち、水分保持能に富んだ弾力性のある角質層を作ること
を見い出した。
Further, the present inventors have conducted intensive studies on the aging phenomenon of the skin. As a result, the elastin is present not only in the dermis but also in the epidermis, and the elastin in the epidermis is decomposed by elastase and radicals. This affects the normal keratinization of epidermal cells and causes skin aging, such as firmness, fine wrinkles, dark spots, and dryness.In other words, inhibiting elastase activity suppresses dermal elastin aging. In addition, it has been found that the elastin in the epidermis is also kept normal, and an elastic stratum corneum rich in water retention ability is produced.

【0007】[0007]

【発明が解決しようとする課題】そこで、本発明は上記
知見に基づいて、皮膚の分化と増殖の制御及びエラスタ
ーゼ活性の抑制効果のいずれか又は双方により弾力性の
あるみずみずしい皮膚を保つことができる皮膚外用剤を
提供することを課題とする。
Therefore, based on the above findings, the present invention can maintain elastic and fresh skin by controlling skin differentiation and proliferation and / or suppressing elastase activity. It is an object to provide a skin external preparation.

【0008】[0008]

【課題を解決するための手段】本発明は上記課題を解決
するためになされたもので、本発明者は、アミノ酸配列
Val Gly Val Ala Pro Glyから
なるオリゴペプチド又は該オリゴペプチドを含むポリペ
プチド、タンパク質若しくはエキスがケラチノサイトの
正常な分化と増殖を維持することを見い出し、該成分を
配合してなることを特徴とする本発明を完成した。
Means for Solving the Problems The present invention has been made to solve the above-mentioned problems, and the present inventors have developed an oligopeptide consisting of the amino acid sequence Val Gly Val Ala Pro Gly or a polypeptide containing the oligopeptide, The present inventors have found that a protein or an extract maintains normal differentiation and proliferation of keratinocytes, and completed the present invention characterized by comprising the components.

【0009】上記アミノ酸配列を有するオリゴペプチド
又は該オリゴペプチドを含むタンパク質等を配合してな
る皮膚外用剤によれば、適度な水分を角層内に保留でき
る結果、弾力性のあるみずみずしい皮膚を保つことがで
きる。
According to an external preparation for skin comprising an oligopeptide having the above amino acid sequence or a protein containing the oligopeptide, an appropriate amount of water can be retained in the stratum corneum, so that elastic and fresh skin is maintained. be able to.

【0010】また、本発明者は、請求項2記載のクロレ
ラ(Chlorella属)、アスコフィラム(学名:
Ascophyllum Nodosum)、オオアザ
ミ(学名: SilybummarianumL.)、
雪積草(学名:Cetella asiatica
(L)Urb)のエキスが、エラスターゼ活性を阻害す
ることを見い出し、該エキスから選ばれた一種又は二種
以上を配合してなることを特徴とする本発明を完成し
た。
[0010] The present inventor has also proposed that chlorella (genus Chlorella) and ascophyllum (scientific name:
Ascophyllum Nodosum), Milk Thistle (scientific name: SilybummarianumL.),
Snowy grass (scientific name: Cetella asiatica)
It has been found that the extract of (L) Urb) inhibits elastase activity, and has completed the present invention characterized in that one or more selected from the extracts are blended.

【0011】本発明の前記エキスのエラスターゼ活性阻
害効果に関するエラスターゼ活性阻害評価について、試
験方法及びその試験結果を以下に説明する。
With respect to the elastase activity inhibition evaluation on the elastase activity inhibition effect of the extract of the present invention, test methods and test results will be described below.

【0012】試験方法 前記エラスターゼ活性阻害評価は、Bieth J.
(参考文献The synthesis and an
alytical use of a highly
sensitive and convenient
substrate of elastase.Bio
chem.Med.1974;11)らの方法に基づい
て実施した。
Test Method The elastase activity inhibition evaluation was carried out according to the method of Bieth J.
(Reference The synthesis and an
everyday use of a highly
Sensitive and convenient
Substrate of elastase. Bio
chem. Med. 1974; 11).

【0013】まず、至適濃度の各評価試料をPBSに加
え、最終100μlに調整した。各試料溶液100μl
にエラスチンの合成基質であるSuccinyl−L−
(alanyl)3−Paranitioanilid
eを50mM Tris−HCL(pH7.8)の条件
で等量加え、18時間インキュベートした。
First, each evaluation sample at an optimum concentration was added to PBS and adjusted to a final volume of 100 μl. 100 μl of each sample solution
Succinyl-L-, a synthetic substrate of elastin
(Alanyl) 3-Paranithioanilid
e was added in the same amount under the condition of 50 mM Tris-HCL (pH 7.8) and incubated for 18 hours.

【0014】その後、410nmの吸光度の変化によ
り、エラスターゼ活性阻害効果を測定した。尚、コント
ロールには、試料無添加の溶液を用いた。
Thereafter, the elastase activity inhibitory effect was measured by the change in absorbance at 410 nm. In addition, the solution to which no sample was added was used as a control.

【0015】試験結果 上記試験の結果を表1に示す。 Test Results Table 1 shows the results of the above test.

【表1】 [Table 1]

【0016】上記クロレラ等のエキスを配合してなる皮
膚外用剤によれば、表皮及び真皮のエラスチンを正常に
保つことができる結果、弾力性のあるみずみずしい皮膚
を保つことができる。
According to the external preparation for skin containing the above extract such as chlorella, the elastin of the epidermis and the dermis can be kept normal, so that the elastic and fresh skin can be kept.

【0017】従って、上記請求項2記載の皮膚外用剤
は、エラスターゼ活性阻害剤であることを好適とする。
Therefore, the external preparation for skin according to claim 2 is preferably an elastase activity inhibitor.

【0018】また、請求項3の如く、上記アミノ酸配列
Val Gly Val AlaPro Glyからな
るオリゴペプチド又は該オリゴペプチドを含むタンパク
質等及び上記クロレラのエキス等を併用配合してなれ
ば、皮膚の分化と増殖の制御及びエラスターゼ活性の抑
制効果が相乗的に発揮され、一層弾力性のあるみずみず
しい皮膚を保つことができる。
Furthermore, if the oligopeptide consisting of the amino acid sequence Val Gly Val AlaPro Gly or the protein containing the oligopeptide and the extract of chlorella are used in combination, the differentiation and proliferation of skin Control and elastase activity inhibitory effects are synergistically exerted, and more elastic and fresh skin can be maintained.

【0019】更に、上記本発明の皮膚外用剤は、抗老化
剤又は角化改善用外用剤であることを好適とする。
Further, the external preparation for skin of the present invention is preferably an anti-aging agent or an external preparation for improving keratinization.

【0020】以下、本発明の構成について詳述する。Hereinafter, the configuration of the present invention will be described in detail.

【0021】本発明の皮膚外用剤は、アミノ酸配列Va
l Gly Val Ala Pro Glyからなる
オリゴペプチドを構成成分として配合したもの、又は前
記オリゴペプチドを含むポリペプチド、タンパク質若し
くはエキスを構成成分として配合したものである。尚、
前記オリゴペプチドは、塩酸塩や酢酸塩等の塩として配
合されてなってもよく、また、前記アミノ酸配列を有す
るものであれば、その起源は問わない。
The external preparation for skin of the present invention has an amino acid sequence Va
An oligopeptide consisting of lGlyValAlaProGly is blended as a constituent, or a polypeptide, protein or extract containing the oligopeptide is blended as a constituent. still,
The oligopeptide may be formulated as a salt such as a hydrochloride or an acetate, and may be of any origin as long as it has the amino acid sequence.

【0022】また、請求項2記載の発明において用いら
れるクロレラ(Chlorella属)、アスコフィラ
ム(学名:Ascophyllum Nodosu
m)、オオアザミ(学名: Silybummaria
numL.)、雪積草(学名:Cetella asi
atica(L)Urb)の植物エキスは、その葉、
茎、花、樹皮、種子、果実又は植物前草を抽出溶媒とと
もに浸漬又は加熱貫流した後、ろ過し、濃縮して得られ
る。
The chlorella (genus Chlorella) and ascophyllum (scientific name: Ascophyllum Nodosu) used in the invention of claim 2 are also used.
m), Milk Thistle (scientific name: Silybummaria)
numL. ), Snowy grass (scientific name: Cetella asi)
atica (L) Urb), its leaves,
A stem, flower, bark, seed, fruit, or plant foreground is immersed or heated through an extraction solvent, and then filtered and concentrated.

【0023】前記抽出溶媒は、通常抽出に用いられる溶
媒であれば特に限定されず、メタノール、エタノール等
のアルコール類、含水アルコール類、アセトン、酢酸エ
チルエステル等の有機溶媒を単独あるいは組み合わせて
用いることができる。
The extraction solvent is not particularly limited as long as it is a solvent usually used for extraction. An organic solvent such as alcohols such as methanol and ethanol, aqueous alcohols, acetone and ethyl acetate is used alone or in combination. Can be.

【0024】また、本発明における前記エキスの配合量
は、皮膚外用剤全量中、乾燥物0.0005〜50.0
重量%、好ましくは0.001〜10.0重量%であ
る。前記配合量が0.0005重量%未満であると、本
発明でいう効果が充分に発揮されず、50.0重量%を
越えると、製剤化が難しいので好ましくなく、また、1
0.0重量%以上配合しても大きな効果の向上はみられ
ないからである。
In the present invention, the amount of the extract is 0.0005 to 50.0% of the total amount of the external preparation for skin,
% By weight, preferably 0.001 to 10.0% by weight. If the amount is less than 0.0005% by weight, the effects of the present invention are not sufficiently exhibited. If the amount is more than 50.0% by weight, it is difficult to formulate the preparation, which is not preferable.
This is because no significant improvement in the effect is observed even when the content is 0.0% by weight or more.

【0025】更に、本発明の皮膚外用剤には、上記必須
の成分以外に通常化粧品や医薬品等の皮膚外用剤に用い
られる成分、例えば、美白剤、保湿剤、酸化防止剤、油
性成分、紫外線吸収剤、界面活性剤、増粘剤、アルコー
ル類、粉末成分、色材、水性成分、水、各種栄養剤等を
適宜配合することができる。
Further, in addition to the above-mentioned essential components, the skin external preparation of the present invention contains components usually used in skin external preparations such as cosmetics and pharmaceuticals, such as whitening agents, moisturizing agents, antioxidants, oily components, and ultraviolet rays. Absorbents, surfactants, thickeners, alcohols, powder components, coloring materials, aqueous components, water, various nutrients, and the like can be appropriately compounded.

【0026】また、本発明の皮膚外用剤とは、例えば、
軟膏、クリーム、乳液、ローション、パック、浴用剤
等、従来より皮膚外用剤として用いられているものであ
ればいずれでもよく、剤型は特に問わない。
The external preparation for skin of the present invention includes, for example,
Ointments, creams, emulsions, lotions, packs, bath preparations and the like may be used as long as they have been conventionally used as external preparations for the skin, and the dosage form is not particularly limited.

【0027】[0027]

【実施例】次に、本発明の実施例について、種々の剤型
の配合例を説明する。尚、本発明はこれに限定されるも
のではない。また、各実施例のオリゴペプチドはアミノ
酸配列Val Gly Val Ala Pro Gl
yからなるオリゴペプチドを示す。
EXAMPLES Examples of the present invention will now be described with reference to examples of various formulations. Note that the present invention is not limited to this. Further, the oligopeptide of each example has an amino acid sequence Val Gly Val Ala Pro Gl
2 shows an oligopeptide consisting of y.

【0028】実施例1 本実施例では、下記に示す処方に基づいてクリームを作
成した。尚、各成分の数値は重量%を示す。 セタノール 2.0 親油型モノステアリン酸グリセリン 3.5 流動パラフィン 10.0 イソノナン酸2−エチルヘキシル 10.0 モノステアリン酸ソルビタン 4.5 メチルポリシロキサン 1.0 N−アシル−L−グルタミン酸ナトリウム 0.5 1,3−ブチレングリコール 5.0 濃グリセリン 10.0 パラベン 0.2 オリゴペプチドの塩酸塩 0.5 クロレラエキス 0.2 アスコフィラムエキス 0.5 オオアザミエキス 0.1 雪積草エキス 0.3 精製水 残量
Example 1 In this example, a cream was prepared based on the following formulation. In addition, the numerical value of each component shows weight%. Cetanol 2.0 Lipophilic glyceryl monostearate 3.5 Liquid paraffin 10.0 2-Ethylhexyl isononanoate 10.0 Sorbitan monostearate 4.5 Methylpolysiloxane 1.0 N-acyl-L-sodium glutamate 0. 5 1,3-butylene glycol 5.0 concentrated glycerin 10.0 paraben 0.2 oligopeptide hydrochloride 0.5 chlorella extract 0.2 ascophyllum extract 0.5 milk thistle extract 0.1 snowpack extract 0. 3 Remaining purified water

【0029】実施例2 本実施例では、下記に示す処方に基づいてエッセンスを
作成した。尚、各成分の数値は重量%を示す。 1,3−ブチレングリコール 5.0 濃グリセリン 10.0 クエン酸 0.02 クエン酸ナトリウム 0.1 ヒアルロン酸ナトリウム 0.2 パラベン 0.2 オリゴペプチドの酢酸塩 0.2 クロレラエキス 2.0 アスコフィラムエキス 2.0 オオアザミエキス 0.2 雪積草エキス 0.2 精製水 残量
Example 2 In this example, an essence was prepared based on the following formulation. In addition, the numerical value of each component shows weight%. 1,3-butylene glycol 5.0 concentrated glycerin 10.0 citric acid 0.02 sodium citrate 0.1 sodium hyaluronate 0.2 paraben 0.2 acetate of oligopeptide 0.2 chlorella extract 2.0 ascophy Lamb extract 2.0 Milk thistle extract 0.2 Snowpack extract 0.2 Purified water

【0030】実施例3 本実施例では、下記に示す処方に基づいてローションを
作成した。尚、各成分の数値は重量%を示す。 エタノール 5.0 ポリオキシエチレン硬化ヒマシ油 0.3 濃グリセリン 3.0 1,3−ブチレングリコール 5.0 クエン酸 0.02 クエン酸ナトリウム 0.1 オリゴペプチドの塩酸塩 0.1 クロレラエキス 1.0 アスコフィラムエキス 1.0 オオアザミエキス 0.1 雪積草エキス 0.1 精製水 残量
Example 3 In this example, a lotion was prepared based on the following formulation. In addition, the numerical value of each component shows weight%. Ethanol 5.0 Polyoxyethylene hydrogenated castor oil 0.3 Concentrated glycerin 3.0 1,3-butylene glycol 5.0 Citric acid 0.02 Sodium citrate 0.1 Oligopeptide hydrochloride 0.1 Chlorella extract 1. 0 Ascophyllum extract 1.0 Milk thistle extract 0.1 Snowpack extract 0.1 Purified water

【0031】[0031]

【発明の効果】以上のように、請求項1記載の皮膚外用
剤によれば、特定のアミノ酸配列を持つペプチドを配合
してなることにより、適度な水分を角層内に保留して、
弾力性のあるみずみずしい皮膚を保ち、結果、たるみの
ない若々しい皮膚をつくることができる。
As described above, according to the external preparation for skin according to claim 1, by blending a peptide having a specific amino acid sequence, an appropriate amount of water is retained in the stratum corneum,
Keeps elastic and fresh skin, resulting in youthful skin without sagging.

【0032】また、請求項2記載の皮膚外用剤によれ
ば、特定のエキスを配合してなることにより、エラスタ
ーゼ活性を阻害して、表皮及び真皮のエラスチンを正常
に保ち、弾力性のあるみずみずしい皮膚を保つことがで
きる結果、たるみのない若々しい皮膚をつくることがで
きる。
Further, according to the external preparation for skin according to the second aspect, the specific extract is added to inhibit the elastase activity, to keep the elastin of the epidermis and the dermis normal and to have elasticity and freshness. As a result of maintaining the skin, youthful skin without sagging can be created.

【0033】従って、上記請求項2記載の皮膚外用剤
は、エラスターゼ活性阻害剤であることを好適とする。
Therefore, it is preferable that the external preparation for skin according to claim 2 is an elastase activity inhibitor.

【0034】また、請求項1記載の成分と請求項2記載
の成分とを併用配合してなれば、皮膚の分化と増殖の制
御及びエラスターゼ活性の抑制の相乗効果によって、よ
り一層若々しい皮膚をつくることができる。
[0034] When the components described in claim 1 and the components described in claim 2 are combined, a more youthful skin is obtained due to a synergistic effect of controlling the differentiation and growth of the skin and suppressing the elastase activity. Can be made.

【0035】従って、上記本発明の皮膚外用剤は、抗老
化剤又は角化改善用外用剤であることを好適とする。
Accordingly, it is preferable that the skin external preparation of the present invention is an anti-aging agent or an external preparation for improving keratinization.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61P 17/12 A61K 31/00 617G 17/00 617 A61K 35/78 35/78 C 35/80 35/80 A 38/00 37/02 (72)発明者 重松 剛 大阪府大阪市北区豊崎3丁目19番3号 ピ アス株式会社内 (72)発明者 堤 雅子 大阪府大阪市北区豊崎3丁目19番3号 ピ アス株式会社内 Fターム(参考) 4C083 AA111 AC022 AC072 AC102 AC122 AC242 AC302 AC352 AC422 AC432 AC442 AC482 AC662 AD152 AD332 AD411 AD412 CC02 CC04 CC05 DD27 DD31 EE06 EE07 EE12 EE13 4C084 AA02 BA01 BA02 BA17 DC41 MA22 MA28 MA63 ZA892 ZC202 ZC522 4C088 AA16 AB26 AB99 AC01 AC03 AC04 AC05 AC06 AC15 BA08 BA10 BA16 MA07 MA63 NA14 ZA89 ZC20 ZC52 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) A61P 17/12 A61K 31/00 617G 17/00 617 A61K 35/78 35/78 C 35/80 35/80 A 38/00 37/02 (72) Inventor Tsuyoshi Shigematsu 3-19-3 Toyosaki, Kita-ku, Osaka-shi, Osaka Pears Co., Ltd. (72) Masako Tsutsumi 3-19-3, Toyosaki, Kita-ku, Osaka, Osaka No.3 Pierce Co., Ltd. F-term (reference) 4C083 AA111 AC022 AC072 AC102 AC122 AC242 AC302 AC352 AC422 AC432 AC442 AC482 AC662 AD152 AD332 AD411 AD412 CC02 CC04 CC05 DD27 DD31 EE06 EE07 EE12 EE13 4C084 AA02 BA01 BA02 BA17 DC41 MA22 MA28 MA63 ZC522 4C088 AA16 AB26 AB99 AC01 AC03 AC04 AC05 AC06 AC15 BA08 BA10 BA16 MA07 MA63 NA14 ZA89 ZC20 ZC52

Claims (6)

【特許請求の範囲】[Claims] 【請求項1】 アミノ酸配列Val Gly Val
Ala Pro Glyからなるオリゴペプチド又は該
オリゴペプチドを含むポリペプチド、タンパク質若しく
はエキスを配合してなることを特徴とする皮膚外用剤。
1. The amino acid sequence Val Gly Val
An external preparation for skin, comprising an oligopeptide comprising Ala Pro Gly or a polypeptide, protein or extract containing the oligopeptide.
【請求項2】 クロレラ(Chlorella属)、ア
スコフィラム(学名:Ascophyllum Nod
osum)、オオアザミ(学名: Silybumma
rianumL.)、雪積草(学名:Cetella
asiatica(L)Urb)のエキスから選ばれた
一種又は二種以上を配合してなることを特徴とする皮膚
外用剤。
2. Chlorella (genus Chlorella), Ascophyllum (scientific name: Ascophyllum Nod)
osum), Milk Thistle (scientific name: Silybumma)
rianummL. ), Snowpack (scientific name: Cetella)
A skin external preparation comprising one or more selected from extracts of asiatica (L) Urb).
【請求項3】 エラスターゼ活性阻害剤である請求項2
記載の皮膚外用剤。
3. The method according to claim 2, which is an elastase activity inhibitor.
The topical skin preparation according to the above.
【請求項4】 アミノ酸配列Val Gly Val
Ala Pro Glyからなるオリゴペプチド又は該
オリゴペプチドを含むポリペプチド、タンパク質若しく
はエキスと、クロレラ(Chlorella属)、アス
コフィラム(学名:Ascophyllum Nodo
sum)、オオアザミ(学名: Silybummar
ianumL.)、雪積草(学名:Cetella a
siatica(L)Urb)のエキスから選ばれた一
種又は二種以上とを配合してなることを特徴とする皮膚
外用剤。
4. The amino acid sequence Val Gly Val
Oligopeptide consisting of Ala Pro Gly or a polypeptide, protein or extract containing the oligopeptide, chlorella (genus Chlorella), ascophyllum (scientific name: Ascophyllum Nodo)
sum), Milk Thistle (scientific name: Silybummar)
ianum mL. ), Snowpack (scientific name: Cetella a)
An external preparation for skin characterized by comprising one or more selected from extracts of siaica (L) Urb).
【請求項5】 抗老化剤である請求項1、2又は4のい
ずれかに記載の皮膚外用剤。
5. The external preparation for skin according to claim 1, which is an anti-aging agent.
【請求項6】 角化改善用外用剤である請求項1、2又
は4のいずれかに記載の皮膚外用剤。
6. The external preparation for skin according to claim 1, which is an external preparation for improving keratinization.
JP10309809A 1998-10-30 1998-10-30 Skin lotion Pending JP2000136124A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP10309809A JP2000136124A (en) 1998-10-30 1998-10-30 Skin lotion

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10309809A JP2000136124A (en) 1998-10-30 1998-10-30 Skin lotion

Publications (1)

Publication Number Publication Date
JP2000136124A true JP2000136124A (en) 2000-05-16

Family

ID=17997517

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10309809A Pending JP2000136124A (en) 1998-10-30 1998-10-30 Skin lotion

Country Status (1)

Country Link
JP (1) JP2000136124A (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002308791A (en) * 2001-04-11 2002-10-23 Pias Arise Kk Ceramidase activity inhibitor, skin care preparation containing the activity inhibitor, cosmetic, and quasi-drug
WO2003000222A2 (en) * 2001-06-22 2003-01-03 Gecomwert Anstalt Cosmetic preparation with anti-wrinkle action
WO2003099248A1 (en) * 2002-05-24 2003-12-04 Johnson & Johnson Consumer Companies, Inc. Composition containing a peptide and a pigment and the use thereof in darkening the skin
JP2004091397A (en) * 2002-08-30 2004-03-25 Fancl Corp Skin aging-preventive composition for preventing and ameliorating epidermis flattening
US6797697B2 (en) * 2001-05-21 2004-09-28 Johnson & Johnson Consumer Companies, Inc. Composition containing a peptide and a pigment and the use thereof in darkening the skin
FR2854897A1 (en) * 2003-05-12 2004-11-19 Sederma Sa COSMETIC OR DERMOPHARMACEUTICAL COMPOSITIONS FOR REDUCING THE SIGNS OF SKIN AGING.
JP2006507257A (en) * 2002-09-13 2006-03-02 コグニス・フランス・ソシエテ・アノニム Method for protecting and adjusting the dermis-epidermal junction
WO2006053688A1 (en) * 2004-11-17 2006-05-26 Henkel Kommanditgesellschaft Auf Aktien Cosmetic and dermatological preparations for the treatment of mature skin
JP2006528935A (en) * 2003-07-25 2006-12-28 ザ プロクター アンド ギャンブル カンパニー Preparation of mammalian keratinous tissue using N-acylamino acid composition
US7381707B2 (en) 2005-06-30 2008-06-03 Johnson & Johnson Consumer Companies, Inc. Treatment of dry eye
FR2957252A1 (en) * 2010-03-09 2011-09-16 Lvmh Rech COSMETIC COMPOSITION
JP2013035808A (en) * 2011-08-10 2013-02-21 Rohto Pharmaceutical Co Ltd Ltbp-4 production promotor
JP2014509631A (en) * 2011-04-01 2014-04-21 ロレアル Use of zingerone or its derivatives to reduce or delay the signs of skin aging
JP2015151390A (en) * 2014-02-18 2015-08-24 共栄化学工業株式会社 Humectant, antiinflammatory agent, antioxidant, skin turnover improver, cell activator and skin-whitening agent
CN107536798A (en) * 2017-08-29 2018-01-05 潘龙花 A kind of female sex organ care compositions
CN108852919A (en) * 2017-05-09 2018-11-23 大江生医股份有限公司 Yellow tang extract is used to adjust the purposes of gene group performance

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002308791A (en) * 2001-04-11 2002-10-23 Pias Arise Kk Ceramidase activity inhibitor, skin care preparation containing the activity inhibitor, cosmetic, and quasi-drug
US6797697B2 (en) * 2001-05-21 2004-09-28 Johnson & Johnson Consumer Companies, Inc. Composition containing a peptide and a pigment and the use thereof in darkening the skin
WO2003000222A2 (en) * 2001-06-22 2003-01-03 Gecomwert Anstalt Cosmetic preparation with anti-wrinkle action
WO2003000222A3 (en) * 2001-06-22 2004-04-29 Gecomwert Anstalt Cosmetic preparation with anti-wrinkle action
WO2003099248A1 (en) * 2002-05-24 2003-12-04 Johnson & Johnson Consumer Companies, Inc. Composition containing a peptide and a pigment and the use thereof in darkening the skin
JP2004091397A (en) * 2002-08-30 2004-03-25 Fancl Corp Skin aging-preventive composition for preventing and ameliorating epidermis flattening
JP2006507257A (en) * 2002-09-13 2006-03-02 コグニス・フランス・ソシエテ・アノニム Method for protecting and adjusting the dermis-epidermal junction
KR101231914B1 (en) * 2003-05-12 2013-02-08 쎄데르마 Cosmetic or dermopharmaceutical composition for reducing the signs of cutaneous ageing
FR2854897A1 (en) * 2003-05-12 2004-11-19 Sederma Sa COSMETIC OR DERMOPHARMACEUTICAL COMPOSITIONS FOR REDUCING THE SIGNS OF SKIN AGING.
JP2007536205A (en) * 2003-05-12 2007-12-13 セダーマ Cosmetic or dermatological composition for inhibiting skin aging phenomenon
JP2006528935A (en) * 2003-07-25 2006-12-28 ザ プロクター アンド ギャンブル カンパニー Preparation of mammalian keratinous tissue using N-acylamino acid composition
WO2006053688A1 (en) * 2004-11-17 2006-05-26 Henkel Kommanditgesellschaft Auf Aktien Cosmetic and dermatological preparations for the treatment of mature skin
US7381707B2 (en) 2005-06-30 2008-06-03 Johnson & Johnson Consumer Companies, Inc. Treatment of dry eye
FR2957252A1 (en) * 2010-03-09 2011-09-16 Lvmh Rech COSMETIC COMPOSITION
JP2014509631A (en) * 2011-04-01 2014-04-21 ロレアル Use of zingerone or its derivatives to reduce or delay the signs of skin aging
JP2013035808A (en) * 2011-08-10 2013-02-21 Rohto Pharmaceutical Co Ltd Ltbp-4 production promotor
JP2015151390A (en) * 2014-02-18 2015-08-24 共栄化学工業株式会社 Humectant, antiinflammatory agent, antioxidant, skin turnover improver, cell activator and skin-whitening agent
CN108852919A (en) * 2017-05-09 2018-11-23 大江生医股份有限公司 Yellow tang extract is used to adjust the purposes of gene group performance
CN107536798A (en) * 2017-08-29 2018-01-05 潘龙花 A kind of female sex organ care compositions

Similar Documents

Publication Publication Date Title
CA2799223C (en) Compositions and methods for stimulating magp-1 to improve the appearance of skin
JP5937965B2 (en) Full seed extract of Moringa species and its use in cosmetic and / or dermatological compositions
JP2000136124A (en) Skin lotion
EA013219B1 (en) A topical skin care composition, a product based thereon and method of treatment
KR100767974B1 (en) A cosmetic composition for reducing the skin pore containing arctium lappa extracts and cold materials
KR20070003907A (en) Agents for sequestering serum aging factors and uses therefore
JP2002193738A (en) Use of at least one extract from at least one azalea plant in composition for treating symptom of skin aging
WO2002053127A1 (en) Agents for inhibiting or restoring skin damage caused by drying and method of evaluating the same
TW201206494A (en) Use of Tiliacora triandra in cosmetics and compositions thereof
TW201136614A (en) Paxillin stimulating compositions and cosmetic uses thereof
JP2011246353A (en) Skin external preparation
JP2005306831A (en) Skin care preparation for external use
US6962712B2 (en) Cosmetic or dermatological composition comprising of a combination of an elastase inhibitor of the N-acylaminoamide family and at least one antifungal agent or at least one antibacterial agent
JP3908126B2 (en) Epidermal keratinization normalizing agent and skin external preparation containing the same
KR101175803B1 (en) Cosmetic composition SBRC for skincell regeneration and anti-aging
JPH08259431A (en) Maillard reaction inhibitor and dermal preparation for external use containing the same
JP4413387B2 (en) Collagen production promoter, elastase activity inhibitor, collagenase activity inhibitor and skin cosmetic
JPH1029924A (en) Antiaging agent
JP2012162487A (en) Whitening agent, anti-aging agent and skin cosmetic
JP3496967B2 (en) Antiplasmin agent
JP4247091B2 (en) Skin anti-aging agent
KR102530481B1 (en) External composition for antiaging comprising osthole
KR102124698B1 (en) Cosmetic composition for improving skin wrinkle or skin aging comprising mixture extract of Chrysanthemum morfiolium, Aloe vera, and Hedera Helix
JP2021187787A (en) Exosome secretagogue, exosome uptake promoter, exosome secretion-promoting beauty composition, and exosome secretion promoting method
JP2021004237A (en) Topical compositions containing n-acyl dipeptide derivatives and glycolic acid

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051021

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20061109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070316